Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Alzheimer Disease
Interventions
[18F]PI-2620
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 22 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 4

NCT05617014
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
Radiation
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 46 more
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes, Youth Onset
Interventions
PI-2620 tracer
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
Interventions
[18F]-PI-2620
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI

NCT04251130
Conditions
Mild Cognitive Impairment
Interventions
2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alzheimer Disease (AD)
Interventions
[18F]GTP1, [18F]PI-2620, [18F]MK-6240
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 2 Interventional Accepts healthy volunteers

PPMI Tau PET Imaging

NCT04906590
Conditions
Parkinson Disease
Interventions
[18F] PI-2620
Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
30 Years to 100 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Alzheimer Disease
Interventions
PI-2620 tracer for Tau PET scan
Diagnostic Test
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
50 Years and older
Enrollment
3,000 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Mild Traumatic Brain Injury
Interventions
[18F]PI-2620
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
25 Years to 54 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Early Phase 1 Interventional Accepts healthy volunteers

Tau PET Imaging in Opioid Use Disorder

NCT05651516
Conditions
Opioid-Related Disorders
Interventions
18F-PI-2620 PET/CT
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

NCT07020026
Conditions
Parkinson's Disease
Interventions
[18F]PI-2620
Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
45 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Recruiting No phase listed Observational Accepts healthy volunteers

Tau Networks in Psychotic Alzheimer's Disease

NCT05847192
Conditions
Alzheimer Disease, Alzheimer Disease With Delusions, Alzheimer Disease With Psychosis
Interventions
[18F]-PI2620 PET scan
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
65 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Manhasset, New York
Conditions
Late Onset Schizophrenia, Delusional Disorder (Late Onset)
Interventions
Tau PET imaging scan
Diagnostic Test
Lead sponsor
Jeremy Koppel
Other
Eligibility
65 Years to 85 Years
Enrollment
16 participants
Timeline
2024 – 2027
U.S. locations
1
States / cities
Manhasset, New York